Safety and Feasibility of PARP1/2 Imaging with ¹⁸F-PARPi in Patients with Head and Neck Cancer.

ABSTRACT:

Purpose

We performed a first-in-human clinical trial. The aim of this study was to determine safety and feasibility of PET imaging with ¹⁸F-PARPi in patients with head and neck cancer.

Patients and methods

Eleven patients with newly diagnosed or recurrent oral and oropharyngeal cancer were injected with ¹⁸F-PARPi (331 ± 42 MBq), and dynamic PET/CT imaging was performed between 0 and 25 minutes postinjection. Static PET/CT scans were obtained at 30, 60, and 120 minutes postinjection. Blood samples for tracer concentration and metabolite analysis were collected. Blood pressure, ECG, oxygen levels, clinical chemistry, and complete blood count were obtained before and after tracer administration.

Results

¹⁸F-PARPi was well-tolerated by all

SUBMITTER: Schoder H 

PROVIDER: S-EPMC7421489 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature